Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA post-marketing powers dropped

This article was originally published in The Tan Sheet

Executive Summary

An amendment that would give FDA the authority to mandate post-market drug safety studies was dropped from the House Agriculture Appropriations bill May 23. The amendment violated a rule prohibiting legislation in appropriation bills, Energy & Commerce/Health Subcommittee Chairman Nathan Deal (R-Ga.) pointed out during same-day floor debate. The bill retained several other amendments that were added during committee including a provision that would limit FDA's ability to grant conflict-of-interest waivers for members of advisory committees. The appropriations measure passed the House by a 378 to 46 vote...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS099409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel